# Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

> **NCT02667223** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Healthy
- Hypercholesterolemia

## Interventions

- **BIOLOGICAL:** Cohort 1: bococizumab 150 mg + rHuPH20
- **BIOLOGICAL:** Cohort 2: bococizumab 300 mg
- **BIOLOGICAL:** Cohort 3: bococizumab 300 mg + rHuPH20
- **BIOLOGICAL:** Cohort 5: bococizumab 450 mg + rHuPH20
- **BIOLOGICAL:** Cohort 4: bococizumab 300 mg + rHuPH20

## Key facts

- **NCT ID:** NCT02667223
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The study was terminated early on July 8, 2016 due to business priorities regarding study execution.
- **Last updated:** 2016-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02667223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02667223, "Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02667223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*